Posters

Mar 2025

ELCC

TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C

Dec 2024

ESMO Immuno-Oncology 2024

TACTI-003 Cohort B: Eftilagimod Alpha (Soluble LAG-3) and Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck Squamous Cell Carcinoma with CPS <1

Nov 2024

CTOS 2024 Annual Meeting

Preliminary results from a phase 2 EFTISARC-NEO trial of neoadjuvant soluble LAG-3 protein eftilagimod alpha, pembrolizumab, and concurrent radiotherapy in patients with resectable soft tissue sarcoma

Sep 2024

DGU

IKF-INSIGHT-005 trial: Avelumab in combination with eftilagimod alpha in unresectable locally advanced/ metastatic urothelial carcinoma

Sep 2024

ESMO Congress 2024

Primary Results from TACTI-003: A Randomized Phase IIb Trial Comparing Eftilagimod Alpha (soluble LAG-3) Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with CPS >1

Publications

Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study

Margarita Majem, Enric Carcereny, Bernard Doger, Tim Clay, Igor Bondarenko, Julio Peguero, Manuel Cobo, Martin Forster, Ewa Kalinka, Gema Maria Garcia Ledo, Laia Vilà Martinez, Wade Iams, Matthew G. Krebs, Begoña Campos, Christian Mueller, Chrystelle Brignone, and Frédéric Triebel, JCO Oncology Advances – May 22, 2025, https://doi.org/10.1200/OA-24-00102

Crystal structure of the human LAG-3-HLA-DR1-peptide complex

Jan Petersen, Carmen Llerena, Bagher Golzarroshan, Camilla Faro, Frédéric Triebel, Jamie Rossjohn https://www.science.org/doi/10.1126/sciimmunol.ads5122

Eftilagimod Alpha (a Soluble LAG-3 Protein) plus Pembrolizumab in Second-Line Metastatic Non-Small Cell Lung Cancer Refractory to Anti-PD-(L)1-based Therapy: Final Results from a Phase II Study

M.G. Krebs ∙ M. Forster ∙ M. Majem ∙ J. Peguero ∙ W. Iams ∙ T. Clay ∙ P. Roxburgh ∙ B. Doger ∙ P. Bajaj ∙ B. Andres ∙ S. Perera ∙ C. Mueller ∙ F. Triebel, JTO Clinical And Research Reports. https://doi.org/10.1016/j.jtocrr.2024.100725

Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma

Martin Forster; Irene Brana; Antonio L. Pousa; Bernard Doger; Patricia Roxburgh; Pawan Bajaj; Julio Peguero; Matthew Krebs; Enric Carcereny; Grisma Patel; Christian Mueller; Chrystelle Brignone; Frederic Triebel, Clinical Cancer Research, OF1–OF9. https://doi.org/10.1158/1078-0432.CCR-24-0473

Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Hans Wildiers, Anne Armstrong, Eveline Cuypere, Florence Dalenc, Luc Dirix, Steve Chan, Frederik Marme, Carolina P. Schroder, Jens Huober, Francois P. Duhoux, Peter Vuylsteke, Agnes Jager, Etienne Brain, Sherko Kuemmel, Zsuzsanna Papai, Catharina Willemien Menke-van der Houven van Oordt, Luca Perjesi, Christian Mueller, Chrystelle Brignone, and Frederic Triebel. Clinical Cancer Research, OF1-OF10. https://doi.org/10.1158/1078-0432.CCR-23-1173